Financial Data and Key Metrics Changes - In fiscal year 2021, revenues increased by over 48% to €190 million compared to €128.4 million in 2020, primarily driven by COVID-19 testing which generated €146.4 million [23][24] - Core business revenue grew by 11% in 2021 to €43.5 million from €39.1 million in 2020, with a significant increase of 34% in Q4 2021 compared to Q4 2020 [24][11] - Overall gross margin for the company was 15% in 2021, down from 35% in 2020, largely due to the lower margins in the COVID segment [35][32] Business Line Data and Key Metrics Changes - The Diagnostics business grew 30% in Q4 2021 and 26% for the full year 2021, with revenues reaching €27.9 million in 2021 compared to €22.1 million in 2020 [12][25] - The Pharma business saw a revenue decrease of 8% year-over-year, from €16.9 million in 2020 to €15.6 million in 2021, although Q4 2021 showed a 40% increase compared to Q4 2020 [27][15] - The Diagnostics segment received an order intake of 57,000 test requests in 2021, a 37% increase from 42,000 in 2020 [25] Market Data and Key Metrics Changes - The company aims to expand its CENTOGENE Bio/Databank to reach 1 million individuals, having added approximately 94,000 individuals in 2021 [50][9] - The rare disease drug market is expected to grow at about 11% annually to $207 billion by 2024, with rare disease drugs capturing approximately 18% of worldwide prescription sales [52] Company Strategy and Development Direction - The company is focusing on three strategic pillars: biopharma partnerships, strengthening the CENTOGENE Bio/Databank, and enhancing the Diagnostics business [47] - CENTOGENE plans to leverage its Bio/Databank to add value to biopharma partners throughout their development plans, aiming to de-risk and accelerate pharma projects [52][54] - The company is also working on decentralization and innovation in its Diagnostics offerings, including the launch of new products and partnerships [58][59] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2022, expecting core business revenues to grow between 15% to 20% year-over-year, with a focus on execution and growth [60] - The company anticipates a relatively flat performance in Q1 2022, with stronger growth expected in the second half of the year as the Pharma segment accelerates [62] - Management highlighted the importance of improving operational efficiencies and reducing corporate expenses while supporting growth initiatives [42] Other Important Information - The company successfully raised approximately €62 million through combined equity and debt financing to strengthen its balance sheet [10] - The COVID-19 testing segment is being phased out, with an expected revenue of approximately €18 million in Q1 2022 before the complete phase-out [31][61] Q&A Session Summary Question: Cash burn and spending priorities for 2022 - Management indicated that the financing secured should extend the company's runway, with more specific details on cash burn expected in future communications [64][65] Question: Timeline for achieving the goal of 1 million samples in the bio bank - The company is on track to achieve the mid-term goal of 1 million patients, with healthy growth in the Bio/Databank [66] Question: Guidance for 2022 core revenue growth and expectations for Diagnostics vs Pharma - The company aims for core revenue growth of 15% to 20%, with a focus on increasing the share of Pharma in the core business [69] Question: Trends in the core diagnostics business and impact of Omicron - The business has been stable, with minimal impact from the Omicron variant reported so far [77] Question: Size of the Pharma outreach team and future additions - The company plans to increase its sales and project management teams to enhance outreach and project execution [79]

Centogene N.V. (NASDAQ:CNTG) Q3 2021 Earnings Conference Call November 24, 2021 8:30 AM ET Company Participants Lennart Streibel - Investor Relations Andrin Oswald - Chief Executive Officer Rene Just - Chief Financial Officer Conference Call Participants Puneet Souda - SVB Leerink Catherine Schulte - Baird Sung Ji Nam - BTIG Operator Ladies and gentlemen thank you for standing by and welcome to the CENTOGENE Q3 2021 Earnings Results. At this time, all participants are in a listen-only mode. After the speake ...

Diagnose. Understand. Treat. CENTOGENE N.V. (CNTG) Q3 2021 Financial Results November 24, 2021 Andrin Oswald, M.D. – CEO René Just – CFO DRAFT - confidential Safe Harbor statement This presentation has been prepared by Centogene N.V. (The "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlaw ...

Table of Contents | --- | --- | --- | --- | |--------------|---------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------| | | | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | | | (Mark One) | | FORM 20-F | | | ☐ | | REGISTRATION STATEMENT P ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...